Sartorius Q2 Earnings Report: Sales up 6.1% to €1.77bn, Shares Fall 5%

Sartorius' shares fell 5% after its half-year report showed a 6.1% sales increase to €1.77 billion, slightly below analyst expectations. Adjusted EBITDA reached €527.3 million, exceeding expectations. The company reaffirmed its 2025 forecast for 6% organic sales growth and a 29-30% adjusted EBITDA margin. Sartorius owns a 10% stake in Swedish company Bico, whose shares slipped 0.5% in morning trading.

Sartorius AG (ETR:SATG) reported its half-year results for 2025, showing a 6.1% increase in group sales revenue to €1.77 billion, slightly below analyst expectations. The company's underlying EBITDA reached €527.3 million, exceeding expectations. Sartorius reaffirmed its 2025 forecast for 6% organic sales growth and a 29-30% adjusted EBITDA margin. The company's shares fell 5% in response to the report, while its 10% stake in Swedish company Bico saw its shares slip 0.5% in morning trading [1].

Sartorius' strong performance in the first half of 2025 was driven by robust sales growth across all business regions. The Americas region recorded a 7.1% increase in constant currencies, while the EMEA region grew by 5.9%, and Asia/Pacific saw a 5.0% increase. The Bioprocess Solutions Division, which accounts for more than three-quarters of Group sales revenue, grew by 8.8% in constant currencies, with underlying EBITDA increasing by 16.5% [2].

However, the Lab Products & Services Division, which specializes in life science research and pharmaceutical laboratories, saw a 4.0% decrease in sales revenue in constant currencies. This division was impacted by weak end markets, with customers remaining cautious about investing in laboratory instruments. The division's underlying EBITDA decreased by 7.1% [2].

Despite the mixed performance, Sartorius remains confident in its market position and competitiveness. The company's management expressed satisfaction with the business results for the first half of the year and reaffirmed its guidance for the full year 2025. The company expects organic sales revenue growth of around 6% for the Group, around 7% in the Bioprocess Solutions Division, and around 1% for Lab Products & Services [2].

The company's strong financial performance is reflected in its robust balance sheet and key financial indicators. The equity ratio stood at 37.8% as of June 30, 2025, and the ratio of net debt to underlying EBITDA was reduced further as planned to 3.8 [2].

Investments in the company's global research and production infrastructure amounted to €161 million in the first half of the year, with a ratio of capital expenditures to sales revenue of 9.1%. The company's shares fell 5% in response to the report, while its 10% stake in Swedish company Bico saw its shares slip 0.5% in morning trading [1].

References:
[1] Investing.com -- Sartorius AG (ETR:SATG) (ETR:SRT) reported a 6.1% increase in group sales revenue for the first six months of 2025, according to financial results released Tuesday. URL: https://www.investing.com/news/stock-market-news/sartorius-reports-61-sales-growth-confirms-2025-guidance-93CH-4144998
[2] EQS News -- Sartorius AG / Key word(s): Half Year Results Sartorius continues growth course; earnings rise at a significantly overproportionate rate (news with additional features) 22.07.2025 / 07:00 CET/CEST. URL: https://www.eqs-news.com/news/corporate/sartorius-continues-growth-course-earnings-rise-at-a-significantly-overproportionate-rate/5fa4bd38-cafc-4f5b-af85-2088feda92cc_en